ZLAB Zai Lab Limited

+0.17  (+1%)
Previous Close 29.9
Open 30
Price To Book 6.96
Market Cap 1747244503
Shares 58,105,903
Volume 339,967
Short Ratio
Av. Daily Volume 180,503

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data released August 24, 2018. Primary endpoint not met.
Fugan (ZL-3101)
Phase 2 interim data released September 2018.
Second-line Hepatocellular carcinoma (HCC)
Phase 3 dosing initiated - noted June 29. 2018.
ZL-2306 (niraparib)
First-line maintenance therapy for platinum-responsive ovarian cancer
China NDA filing announced December 12, 2018.
ZL-2306 (niraparib)
Recurrent platinum-sensitive ovarian cancer
Phase 3 portion of Phase 1/3 trial has been initiated - September 10, 2018. Phase 1 data presented at ASCO GI January 17, 2019 noted 19% ORR.
FPA144 + chemo (FIGHT)
Gastric and gastro-esophageal junction cancer
Phase 3 trial initiation announced August 28, 2018.
ZL-2306 (niraparib)
Small cell lung cancer

Latest News

  1. Zai Lab Announces Presentations at March Conferences
  2. Zai Lab Announces Financial Results and Corporate Update for Full Year 2018
  3. Macrogenics Inc (MGNX) Q4 2018 Earnings Conference Call Transcript
  4. Zai Lab to Announce Full Year 2018 Financial Results
  5. Zai Lab to Present at the 8th Annual SVB Leerink Global Healthcare Conference
  6. The Daily Biotech Pulse: Galapagos-Evotec Forge Fibrosis Partnership, Sanofi Earnings, Alector To Debut
  7. MacroGenics stock spikes from positive results of cancer drug trial
  8. Zacks.com featured expert Kevin Matras highlights: Meet, Zai Lab, NanoString Technologies, OSI Systems and AudioEye
  9. Zai Lab Announces the Appointment of Immuno-Oncology Pioneer, Lieping Chen, M.D., Ph.D., to its Scientific Advisory Board
  10. 5 Stocks With Recent Price Strength to Enhance Your Return
  11. Priority Review Granted to Zai Lab’s NDA Application for ZEJULA (Niraparib) in China
  12. Moving Average Crossover Alert: Zai Lab Limited
  13. Will Zai Lab Continue to Surge Higher?
  14. Peninsula biotech sheds 20% of jobs to focus on drugs closer to finish line
  15. Zai Lab Completes Enrollment of China Pivotal Trial of Niraparib as Second-Line Maintenance Therapy for Ovarian Cancer in China
  16. Zai Lab Announces Launch of Optune® in Hong Kong for Patients with Glioblastoma Multiforme
  17. Zai Lab to Present at the 37th Annual J.P. Morgan Healthcare Conference
  18. Zai Lab Limited (ZLAB): Are Hedge Funds Right About This Stock?
  19. Zai Lab Announces Acceptance of NDA Submission of ZEJULA (Niraparib) in Mainland China by the NMPA
  20. George Soros Bought These 2 Healthcare Stocks in the Third Quarter